![](https://mpfshstrg.blob.core.windows.net/mpf-uat-common-resources/Images/monograph/table.gif)
Previously vaccinated children from 12 months of age, adolescents and adults: Nimenrix may be given as a booster dose to individuals who have previously received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine (see Pharmacology: Pharmacodynamics under Actions).
Special populations: Individuals who have underlying conditions predisposing them to meningococcal infection due to anatomic or functional asplenia (such as sickle cell disease) may receive at least one dose of Nimenrix (see Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
Method of administration: Immunization should be carried out by intramuscular injection only.
In infants, the recommended injection site is the anterolateral aspect of the thigh.
In individuals from 1 year of age, the recommended injection site is the anterolateral aspect of the thigh or the deltoid muscle (see Precautions and Interactions).
For instructions on reconstitution of the medicinal product before administration, see Special Precautions for Disposal and Other Handling under Cautions for Usage.